In this study, through an anticancer drug screen, we discovered that DNA-PK inhibitors can cooperate with oncolytic virus M1 by promoting virus replication and increasing the virus-mediated DNA damage response in refractory tumour cells (Fig. 8). Here, PRKDC is linked to neoplasm.